Advertisement
Singapore markets close in 3 minutes

  • Straits Times Index

    3,290.10
    +17.38 (+0.53%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE 100

    8,083.24
    +38.43 (+0.48%)
     

  • Bitcoin USD

    66,562.57
    +421.24 (+0.64%)
     

  • CMC Crypto 200

    1,435.15
    +11.05 (+0.78%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • Dow

    38,503.69
    +263.71 (+0.69%)
     

  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     

  • Gold

    2,330.30
    -11.80 (-0.50%)
     

  • Crude Oil

    82.98
    -0.38 (-0.46%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • FTSE Bursa Malaysia

    1,571.47
    +9.83 (+0.63%)
     

  • Jakarta Composite Index

    7,176.02
    +65.21 (+0.92%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

NY-based co. closing Syracuse-area lab in July

NY-based co. closing Syracuse-area lab employing 45; firm is partner in $250M Buffalo project

Associated Press

CICERO, N.Y. (AP) -- An Albany-based pharmaceutical company that's part of a $250 million economic development project in Buffalo is shutting down its Syracuse-area research center, eliminating 45 jobs.

Albany Molecular Research Inc. announced Wednesday that it will close its 12-year-old facility in Cicero on July 15. Some employees will be transferred to Albany, Cedarburg, Wis., England and India.

News of the cost-cutting move comes nearly three weeks after the state-run Empire State Development Corp. voted to approve $50 million in funding for the Buffalo Medical Innovation and Commercialization Hub.

Albany Molecular Research is a partner in the planned $250 million pharmaceutical research and development facility along with Fort Schuyler Management Co., the state College of Nanoscale Science and Engineering, and the Buffalo Niagara Medical Campus.

Plans call for the Buffalo research center to create 250 jobs by 2020.